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ABSTRACT
Introduction Parents who receive the diagnosis of a life- 
threatening, complex heart defect in their fetus or neonate 
face a difficult choice between pursuing termination (for fetal 
diagnoses), palliative care or complex surgical interventions. 
Shared decision making (SDM) is recommended in clinical 
contexts where there is clinical equipoise. SDM can be 
facilitated by decision aids. The International Patient Decision 
Aids Standards collaboration recommends the inclusion 
of values clarification methods (VCMs), yet little evidence 
exists concerning the incremental impact of VCMs on patient 
or surrogate decision making. This protocol describes a 
randomised clinical trial to evaluate the effect of a decision 
aid (with and without a VCM) on parental mental health and 
decision making within a clinical encounter.
Methods and analysis Parents who have a fetus or neonate 
diagnosed with one of six complex congenital heart defects 
at a single tertiary centre will be recruited. Data collection for 
the prospective observational control group was conducted 
September 2018 to December 2020 (N=35) and data 
collection for two intervention groups is ongoing (began 
October 2020). At least 100 participants will be randomised 1:1 
to two intervention groups (decision aid only vs decision aid 
with VCM). For the intervention groups, data will be collected at 
four time points: (1) at diagnosis, (2) postreceipt of decision aid, 
(3) postdecision and (4) 3 months postdecision. Data collection 
for the control group was the same, except they did not receive 
a survey at time 2. Linear mixed effects models will assess 
differences between study arms in distress (primary outcome), 
grief and decision quality (secondary outcomes) at 3- month 
post- treatment decision.
Ethics and dissemination This study was approved by the 
University of Utah Institutional Review Board. Study findings 
have and will continue to be presented at national conferences 
and within scientific research journals.
Trial registration number NCT04437069 (Pre- results).
INTRODUCTION
Background and rationale
Congenital heart disease occurs for about 
40, 000 live births per year; of these, about 
2%–3% are life- threatening congenital heart 
defects (CHDs).1–3 Even with early interven-
tion those diagnosed with life- threatening 
CHDs have frequent readmissions, require 
additional interventions and typically face a 
shortened life span.4 A diagnosis of a severe, 
life- threatening CHD in a fetus or neonate is 
an unexpected and emotionally distressful 
event for parents who must then decide 
between termination (when diagnosed prena-
tally), palliative care or surgery.5–8 Parents 
experience significant grief,9 10 distress, 
depression and anxiety11–13 surrounding this 
difficult decision, which can compromise 
their mental health.14–16
Shared decision making (SDM) is an 
approach for supporting patient engage-
ment with clinicians that is particularly useful 
for contexts, such as life- threatening CHD, 
which involve clinical equipoise and value- 
laden, complex decisions.17–21 Decision aids 
are tools that improve the SDM process and 
include information on treatment options 
that are evidence based, balanced and help 
people clarify their values.4 22 Decision aids 
increase patients’ knowledge, and engage-
ment related to the diagnosis and treatment 
Strengths and limitations of this study
 ► One study strength is that this is a randomised clin-
ical trial design with clinically relevant, validated 
outcome measures.
 ► A second strength is that this study will add to the 
limited literature on the effectiveness of value clarifi-
cation methods in real- word clinical contexts.
 ► Given that the study takes place at one tertiary cen-
tre, there is potential limitation of decreased diver-
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decision making. In addition, studies have found greater 
concordance between patients’ preferences and treat-
ment received, improved patient–provider communica-
tion, and reduced uncertainty and decisional conflict in 
those receiving decision aids.23
The International Patient Decision Aids Standards 
(IPDAS) Collaboration developed criteria for a well- 
designed decision aid.24 Values clarification methods (ie, 
processes that aid patients in clarifying their values and 
goals in order to improve alignment between their pref-
erences and their treatments) were included as a critical 
component. Although some studies have found posi-
tive effects of values clarification methods on decision 
outcomes, there are few rigorous studies in real- world 
clinical contexts that evaluate whether values clarification 
methods improve key outcomes, prompting calls for addi-
tional research.24–26
Objectives and hypothesis
The main objective of the study is to evaluate the effect 
of a decision aid with and without a values clarification 
method on longitudinal parent mental and physical 
health, decision making and clinical encounter outcomes 
(eg, quality of clinician consultation and risk communi-
cation). Since no prior data on decision aid use in CHD 
exist, we will also compare parents who receive the deci-
sion aid to parents who do not (prospective observational 
control group enrolled during decision aid development) 
on the aforementioned outcomes.
We hypothesise that participants who receive the deci-
sion aid with the values clarification method will report 
less distress (primary outcome), reduced grief and better 
decision quality (secondary outcomes) relative to partic-
ipants who receive the decision aid only across 3 months 
post- treatment decision. We also hypothesise that partic-
ipants who receive the decision aid with or without the 
values clarification method will report reduced distress, 
grief and better decision quality relative to participants 
who are in the prospective observational control group.
We will also test the impact of the decision aid with 
a values clarification method on several exploratory 




This is a randomised clinical trial examining the effec-
tiveness of a decision aid and values clarification method. 
There are two intervention groups and one prospective 
observational control group. Data collection for the 
prospective observational control group was conducted 
September 2018–December 2020 (N=35) and data collec-
tion for the intervention groups (the primary analytic 
sample) began October 2020 and is ongoing. The flow of 
the study is outlined in figure 1.
Study setting
This is a single- site study at a children’s hospital in 
the Intermountain West. Physicians at this hospital 
perform >650 fetal echocardiograms with about 125 new 
complex CHD diagnoses annually.
Participants and eligibility criteria
To be eligible for the study, parents must be at least 18 
years old who have a fetus or neonate diagnosed with 
a complex, life- threatening CHD (whether diagnosed 
prenatally or postnatally). While the decision aid was 
being developed, the control group was recruited with 
these guidelines. The decision aid was developed to 
provide information on the following six CHD diagnoses: 
truncus arteriosus with greater than moderate truncal 
valve regurgitation, pulmonary atresia with intact ventric-
ular septum with a severely hypoplastic right ventricle 
that will require single ventricle palliation, complex 
single ventricle, complex single ventricle with heterotaxy, 
hypoplastic left heart syndrome and Ebstein anomaly of 
the tricuspid valve with greater than moderate regurgita-
tion. These diagnoses were chosen as they were deemed 
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preference sensitive in that surgical intervention, pallia-
tive care and termination were all medically reasonable 
treatment options by expert consensus. Thus, in order to 
be eligible for one of the two intervention groups, the 
fetus/neonate must be diagnosed with one of the six 
aforementioned diagnoses.
Recruitment and consent
When a fetus/neonate is diagnosed with a qualifying 
CHD, a paediatric cardiologist will evaluate the diag-
nosis to confirm eligibility for the study. Patients consult 
with a clinician immediately after the diagnosis. Then, 
they are approached by research staff for study partici-
pation. When an eligible fetus/neonate is identified, 
the parent(s) will be approached by the study team and 
invited to participate in the study. One or both parents 
may participate. Interested participants receive a link 
to complete the informed consent through a Research 
Electronic Data Capture (REDCap). If both parents 
consent to participation, they will receive separate links 
to complete their own informed consent and surveys. For 
the intervention groups, the decision aid is initiated by 
the parent, independent of the provider or coordinator. 
Both the control and intervention groups consult with 
clinicians as they decide which treatment to pursue.
Randomisation
Participants will be randomised using REDCap (Health 
Insurance Portability and Accountability Act (HIPAA)- 
compliant remote data capture system) into one of two 
intervention groups, described below, after completing 
the baseline survey. Participants will not be explicitly told 
which group they were randomised to. Both interven-
tion groups will receive the same decision aid, but one 
arm will receive a values clarification method integrated 
within the decision aid, while the other group will get the 
decision aid without the values clarification method. The 
decision aid is an app on an Amazon Fire tablet, which 
is either given to the parent(s) in clinic if they complete 
the baseline survey and consent in person, or is mailed to 
their home if they complete the consent outside of clinic. 
The tablet remains in their possession for the duration of 
the study so that they can consult the decision aid as often 
as they would like.
Development of decision aid and values clarification method
We used data from focus groups of parents who had a 
fetus/neonate diagnosed with a complex CHD, as well as 
semistructured interviews with family and provider stake-
holders to identify important content to include in the 
digital decision aid.27 28 The tool was developed through 
an iterative process of content drafting by the develop-
ment team followed by multiple rounds of content review 
and revision with the research team, parent partners, and 
healthcare providers in relevant fields (eg, paediatric 
cardiologists, surgeons, social workers, palliative care 
experts). The team gathered stories about parents’ expe-
riences during several individual and group interviews.
The research team also developed a values clarification 
method. We began by examining qualitative data from 
the focus groups and interviews related to factors influ-
encing parents’ choices and identifying key elements that 
had influenced parents’ decision. The team then engaged 
in multiple workshop sessions, discussing how best to 
describe components of each value, with parent partners 
providing input on draft versions of these descriptions. 
The values clarification method interface was developed 
through an iterative process of creating alpha versions, 
testing and revision.
Patient and public involvement
Three parents (two females and one male) whose chil-
dren were diagnosed with complex CHD were invited 
to serve as parent collaborators. Discussions with these 
parents informed the design and development of the 
decision aid, outcome measures that were chosen and 
methods of recruitment for the study.
Interventions and comparators
Prospective observational control group
Participants in the prospective observational control 
group did not receive the decision aid or values clarifica-
tion method. Participants were enrolled during the devel-
opment of the decision aid to prevent contamination by 
providers or other families exposed to the decision aid. 
Participants received standard clinical care.
Decision aid
The intervention group receives a decision aid after 
diagnosis and then continues with standard care. The 
decision aid includes eight sections, which are broadly 
described in table 1. Section 5 is individualised to each 
participant to show information specific to their fetus/
neonate’s diagnosis. Participants are given the decision 
aid, which is an app that is loaded onto an Amazon Fire 
tablet (one per family).
Values clarification method
The values clarification method is designed to help partic-
ipants clarify the choice that feels better for them and 
their family. For those randomised to receive the values 
clarification method, the decision aid includes an extra 
module, What Matters Most to You. The goal of this exer-
cise is to help participants think through some short- term 
and long- term consequences of their decision. When 
faced with a life- threatening diagnosis, there are many 
consequences to consider, and participants may not know 
how they feel about each of them or how to weigh them 
by importance or value. To begin, participants choose 
two of the possible treatment decision options (surgery, 
comfort care and ending the pregnancy) and compare 
them in 10 different topic areas. Some examples of the 
topics are: time in the hospital, the risk that the child will 
have impairments, financial issues and life in adulthood. 
The purpose of choosing two potential decisions at a time 
is to put them on a clear spectrum in a preference scale, 
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in terms of determining weights. For each topic, there is 
a sliding scale between the two choices where they drag 
the slider to show how much they prefer one choice over 
another. At the end, they are shown a summary of which 
choice they preferred for each category. Participants 
are not issued a definitive result; the values clarification 
method allows them to look at a summary of their choices 
and draw their own conclusion about what they chose. 
They may repeat the exercise, selecting other options to 
compare.
After the interventions were developed in English, the 
decision aid and values clarification method were trans-
lated into Spanish by certified translators in the Univer-
sity of Utah’s Office of Research Participant Advocacy (as 
were consent documents and survey measures).
Outcomes
All study measures were categorised into three concep-
tual domains: parental mental and physical health, 
decision- making quality and clinical encounter (eg, 
consultation quality) in table 2. The primary outcome 
is distress, measured by the Brief Symptom Inventory 
Global Severity Index.29 The cosecondary outcomes are 
perinatal grief and decision quality (ie, adequate knowl-
edge and concordance between participants’ preferences 
and treatment decision).30 31 Additional exploratory 
outcomes will also be measured. Descriptions of all study 
measures and time points for survey data collection are 
included in table 2. Parent characteristics will be exam-
ined as potential covariates.
Sample size and power calculation
At least 100 families will be randomised 1:1 to the two 
intervention groups, allowing up to two parents to partic-
ipate per fetus/neonate. Our sample size calculations 
were based on the primary comparison between DA with 
and without the VCM. Based on our previous work,32 we 
assume ≥80% retention, a 3- month pre–post R≥0.5, an 
average of ≥1.75 participating parents per participating 
family, an intraclass correlation between parents in the 
same family ≤0.50, and ≥50 families randomised to each 
of the intervention groups (decision aid only and deci-
sion aid with values clarification method). Using these 
assumptions, the mixed effects model will provide 80% 
power with two- sided α=0.05 to detect a mean difference 
in the primary outcome, distress, equal to 0.50 of 1 SD. 
This represents a medium effect size in Cohen’s termi-
nology.33 Assuming a pooled SD in the global distress of 
0.56 units,32 the 0.50 SDs represents a minimum detect-
able effect of 0.28 units.
Data collection
Potentially eligible parents are identified by the provider. 
Following provider consultation, a study team member, 
trained in interacting with families going through highly 
emotional medical events, assesses if this is an appropriate 
Table 1 Decision aid content
1. 
You are not alone
This introductory video (07:53 min), is intended to normalise the experience and set the stage before 
some of the more technical information in the tool. Key messages are: this is a difficult time for you, 
it’s OK to cry, you didn’t cause this, and you are the most qualified to make this decision. The video 
also describes the goals of the tool.
2. How the heart works This section includes animations and information on the cardiovascular system, normal fetal and 
postfetal heart circulation, defects that can take place during heart development that lead to 
abnormal heart function, and a glossary of medical terms.
3. What is a congenital heart defect? This section defines congenital heart defects and how they are caused and diagnosed.
4. How we talk about congenital heart 
defects
This section introduces parents to topics and terms that are often used when discussing congenital 
heart defects, including statistics, diagnosis variability, survival and quality of life (eg, developmental 
delay in cognitive abilities)
5. Learn more about your baby’s 
diagnosis
This section shows parents individualised information specific to their fetus/neonate’s diagnosis. 
Diagnoses available in this section include hypoplastic left heart syndrome, complex single ventricle, 
complex single ventricle with heterotaxy (isomerism), pulmonary atresia with intact ventricular 
septum, Ebstein’s anomaly of the tricuspid valve (with severe leak) and truncus arteriosus. Each 
diagnosis profile includes animated videos depicting the defect, statistics related to how common 
the defect is, other associated conditions, risks of having another child with the defect and expected 
outcomes without treatment.
6. Learn more about your choices This is divided into three sections: surgery, comfort care and ending the pregnancy. Each section 
begins with a ‘What to Expect’ overview and includes a description of the medical team members 
who may be involved, financial implications, living with this decision, and links to other websites and 
support groups. Additional information is tailored to each choice.
7. Firsthand experiences This section contains stories from parents who chose comfort care, surgery or ending the pregnancy, 
in which they describe their personal experiences. Five stories are provided for each of the three 
choices, reflecting a variety of different outcomes. Surgery stories include examples where the 
child had no serious medical complications growing up, examples where the child does have 
complications, and examples where the child did not survive postsurgery.
8. Questions you can ask your doctor This is a list of possible questions parents may wish to ask care providers. Parents can checkmark 
the questions they wish to take with them to their doctor, and the tool will email them just these 
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Table 2 Study outcomes, descriptions and survey measure time points
Measure Description
Measure time points
Time 1 Time 2 Time 3 Time 4
Primary outcome
Mental and physical health outcomes
Distress29 Brief symptom inventory Global Severity Index of Global 
Distress: a validated scale of 53 questions that indicate the 
degree of stress the participant has experienced within the 
previous 7 days. Answers range on a 5- point Likert scale from 
0=not at all to 4=extremely.
X X X X
Secondary outcomes
Decision making outcomes
Perinatal grief30 Twenty- seven questions measuring grief, coping, and despair 
following the death of a child. Rated on a 5- point Likert scale 




Six questions on parent’ decisional values (eg, ‘How important 
it is to you that your child have as little pain and discomfort 
from treatment as possible?’) rated on a 6- point Likert scale 
from 1=most important to 6=not as important.
  X X X
Decision quality 
(knowledge)31
Twenty- six questions assessing the participants’ knowledge 
of treatment options for CHD in two domains. The first domain 
regards understanding about CHD diagnosis and what the 
heart does, the available options, and the outcomes of comfort 
care. The second domain regards understanding about the 
outcomes of surgery/intervention and the impact of CHD on 
family. 21 of the questions use a dichotomous response format 
(either ‘true/ false’ or ‘yes/no’); five questions are multiple 
choice.
  X X X
Exploratory outcomes
Mental and physical health outcomes
Mental and physical 
functional health41
Short Form Health Survey (SF- 12): Twelve items measuring the 
respondents’ health across multiple dimensions. Answers rated 
on a 5- point Likert scale ranging from 1=excellent to 5=poor for 
three questions; answers are given in a dichotomous (yes/no) 
format for four questions; answers are given on a 6- point Likert 
scale ranging from 1=all of the time to 6=none of the time for 
three questions; answers are given in a trichotomous format 
(yes, limited a little; yes, limited a lot; no, not limited at all) for 
the final two questions.
X     X
Parental quality of life42 Impact of Child with Congenital Anomalies on Parents (ICCAP) 
Questionnarie: Thirty- two questions to assess the impact on 
parental quality of life. Four questions ask about contact with 
caregivers, six ask about support from social networks, five 
ask about partner relationships, four ask about the participant’s 
state of mind, and the remaining thirteen ask about fear and 
anxiety. Answers range on a 4- point Likert scale that ranges 
from 1=strongly disagree to 4=strongly agree, with a ‘not 
applicable’ option.
    X X
Decision- making outcomes
Preference for SDM43 Adaption of Degner and Sloagan’s Control Preference Scale- A 
single question on how participants plan to make the decision. 
Responses include 1=My doctor(s) will make the decision with 
little input from me, 2=My doctor(s) will make the decision but 
will seriously consider my opinion, 3=My doctor(s) and I will 
make the decision together, 4=I will make the decision after 
seriously considering my doctor(s) opinion, 5=I will make the 
decision with little input from my doctor(s).
X X X
Preparation for decision 
making44
A validated scale which will assess participants' perspectives 
of the DA’s usefulness in preparing them to communicate with 
their clinicians and for SDM. These questions are answered on 
a Likert scale ranging from 1=not at all to 5=a great deal.


























































































































Time 1 Time 2 Time 3 Time 4
Decision self- efficacy45 Eleven questions to assess self- efficacy for making an informed 
choice (eg, getting needed information, asking questions, 
expressing opinions) using a 5- point Likert scale ranging from 
0=not at all confident to 4=extremely confident.
X X X   
Decision conflict46 Sixteen questions measuring: (1) perceptions of uncertainty in 
choosing options, (2) feelings of having adequate knowledge 
and clear values, and (3) effective decision making. All items 
use a 5- point Likert scale ranging from 0=strongly disagree to 
4=strongly agree.
  X X X
Decision regret47 Five questions asking participants to reflect on the decision 
they made about which treatment option they chose for their 
child. All questions assessed on a 5- point Likert scale from 
1=strongly disagree to 5=strongly agree.
      X
Use of information 
sources
Extent that participants consulted any of 11 sources of health 
information. Two sources are about personal relationships (ie, 
relatives and friends), three are about mass media (ie, exposure 
to television/movies, magazines and books about CHD), two 
are educational/research sources (eg, scientific journals) and 
the remaining four are about providers, support groups, other 
parents who have a child with CHD, and spiritual or religious 
advisor. Answers rated on a 5- point Likert scale ranging from 
1=never to 5=a great deal.
  X     
Treatment choice Treatment choice will be assessed by asking participants to 
identify which treatment they chose. Using electronic health 
records, we will record the child’s actual treatment in case of 
parental change of mind or misreport.
  X X X
Acceptability of DA Participants answered five questions about if they used the 
DA before their appointment or during their appointment, their 
likelihood to recommend the DA, the amount of information 
presented, and if the DA seemed biased.
  X     
Clinical encounter outcomes
Combined Outcome 





Ten questions on 5- point scale (1=strongly disagree, 5=strongly 
agree) to evaluate the participant’s perspective of the 
effectiveness of risk communication and treatment decision 
making in clinician consultations.
  X   
Consultation quality49 Participants complete two questions that measure the quality 
of consultation. One measures the perceived usefulness of 
consultation on a seven point Likert scale that ranges from 
0=not at all useful to 6=very useful. The second question 
measures participants’ perspective regarding whether the 
clinician was biased towards any certain treatment.
X     X
Parents’ characteristics and survey feedback
Demographics Participants indicate their gender, education, race, ethnicity, 
number of children, religion, marital status and whether or not 
they have health insurance.
X       
Literacy50 Three validated, brief questions identifying participants with 
inadequate health literacy.
X       
Numeracy51 A validated scale of 8 questions that distinguish an individual’s 
quantitative ability without asking overly- invasive questions. 
Answers are rated on a 6- point Likert scale ranging from 
1=not at all good/never to 6=extremely good/very often for six 
questions, 1=always prefer percentages to 6=always prefer 
numbers for one question, and 1=always prefer percentages to 
6=always prefer words for one question.
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time to approach them about the study. If the parents are 
too distressed, they are not approached at the time of the 
visit but asked if they would be willing to speak to research 
staff later. If the parents are deemed approachable by the 
trained staff, the study is presented using an informational 
pamphlet, and the potential participant(s) are encour-
aged to follow the link or QR code on the pamphlet if 
they would like to participate in the study. The parents 
who were given the link are recorded in a recruitment 
tracker. All parents who follow the link on their own are 
consented to participate in the study and recorded in 
REDCap. This usually happens with parents whose fetuses 
are prenatally diagnosed, and they follow the link from 
their home electronic devices. If the neonate was postna-
tally diagnosed, the parents are approached in the same 
manner in the hospital and are given the opportunity 
to consent and participate in the study using a tablet in 
person. Parents who are found to be ineligible or who 
decline participation will be recorded along with the 
reason.
Data abstraction
When screening for eligibility, the fetus/neonate diag-
nosis (verified by a paediatric cardiologist) and date of 
diagnosis will be abstracted. Once enrolled in the study, 
gestational age at birth, the presence of other syndromes/
birth defects and the dates of surgery (if applicable) will 
be abstracted from the medical record and documented. 
Further surgery dates are recorded by the research 
coordinator.
Surveys
Participants in the prospective observational control 
group filled out surveys at three time points: (1) base-
line, (2) postdecision and (3) 3 months postdecision (see 
table 1 for an overview of measurements). There are four 
survey time points for the intervention groups: (1) base-
line, (2) postviewing of the decision aid (or decision aid 
and values clarification method) but prior to making the 
decision, (3) postdecision and (4) 3 months postdecision. 
Surveys are administered via REDCap by sending an 
email to the participant with a survey link. Participants 
may request paper surveys to be mailed to them. If the 
participant does not access the survey link, they will be 
contacted by phone or in person during a routine clinic 
visit to ask them to fill out the survey or will be mailed a 
paper survey.
Data management and monitoring
Adverse events that occur during data collection will be 
recorded by the study coordinator, along with any circum-
stances that make particular participants unique. In this 
way, unanticipated data points during analysis may be 
explained and accounted for. Additionally, information 
about mental health resources are given to participants 
at the end of each survey, including a 24- hour, 7 days- a- 
week phone crisis service that is staffed by mental health 
professionals providing emotional support, assistance, 
crisis interventions and suicide preventions to individ-
uals experiencing emotional distress or psychiatric crisis. 
The social worker at the children’s hospital also has their 
contact information listed for participants to be able to 
reach out.
Frequent reports will be run to detect data errors or 
missing data. Any issues will be addressed during a weekly 
meeting between the study coordinator, postdoctoral 
fellow(s) and the principal investigator.
Data analysis plan
After data collection, we will use standardised mean differ-
ences to assess balance between intervention groups in base-
line levels of study endpoints and other potential prognostic 
baseline indicators, including participants’ age, race and 
comorbidities. Outcome variables exhibiting substantial skew-
ness may be transformed to better approximate normality. 
All participants will be analysed in their assigned intervention 
group according to intention- to- treat, irrespective of adher-
ence to viewing the decision aid or completing the values 
clarification method. Although multiple outcomes will be 
considered, we have designated a single primary outcome 
Measure Description
Measure time points
Time 1 Time 2 Time 3 Time 4
Religiosity52 Two items asking ‘How often do you attend church or other 
religious meetings’ (1=Never to 6=More than once/week) and 
‘How often do you spend time in private religious activities, 
such as prayer, meditation or Bible study’ (1=Rarely or never to 
6=More than once a day)
X       
Assessing Survey 
Burden
Six yes/no questions asked if the survey had burdensome 
questions, one 5- point Likert scale question asked about how 
useful the participant perceived the survey would be (1=not at 
all useful and 5=very useful), two 5- point Likert scale questions 
asked participants to rate how burdensome/time consuming 
the survey was from 1=time consuming/burdensome to 
5=quick/easy.
X X X X
Time 1=at diagnosis, Time 2=postreceipt of DA, Time 3=postdecision, Time 4=3 months postdecision.
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(the Brief Symptom Inventory Global Severity Index of global 
distress, described above) and a single primary compar-
ison time for this outcome at 3 months.34 We do not plan 
formal multiple comparison adjustments for secondary and 
exploratory outcomes. Results for secondary and exploratory 
outcomes will support or qualify the analyses of the primary 
outcome, and will be interpreted based on the overall pattern 
of results with awareness that some nominally significant 
relationships may be false positive findings in the context of 
multiple analyses. If there is sufficient power to detect differ-
ences, exploratory sub- group analyses may be conducted to 
detect differences by factors such as pre vs post- natal diag-
noses, CHD diagnosis, provider specialty, and parent dyads. 
We also do not plan formal multiple comparison adjustment 
for the randomised comparison between intervention groups 
(decision aid only vs decision aid with values clarification 
method) and the non- randomised comparison (decision aid 
vs control), as these comparisons address distinct hypotheses 
and are thus appropriate for evaluation on a comparison wise 
basis.35
Determining intervention effects on study endpoints
Randomised comparisons between intervention groups (decision 
aid only vs decision aid with values clarification method)
The primary outcome, distress, measured at postdecision aid, 
postdecision and 3 months will be compared between groups 
by applying restricted maximum likelihood estimation to a 
linear mixed effects model36 with fixed provider effects and 
random family effects to account for clustering of outcomes 
due to these factors and an unstructured residual covariance 
model to account for serial correlation across the three longi-
tudinal assessments. Inclusion of fixed effects for provider is 
appropriate since families are randomised to the two inter-
vention groups for each provider and may improve statistical 
power by controlling for provider variation. The model will 
also include fixed effects for randomised assignment as well 
as the baseline distress.34 Additional prespecified covariate 
adjustment is not planned, as we are not aware of further 
baseline factors that are likely to have a strong association with 
the 3- month distress once the baseline distress is accounted 
for.35 However, should a prognostic baseline factor exhibit 
imbalance between the randomised groups, a post hoc sensi-
tivity analysis will be performed with covariate adjustment for 
that factor to assess the robustness of the results to the imbal-
ance. The 3- month comparison will represent the primary 
contrast for assessing the effect of the decision support inter-
vention. It is possible that the full mixed effects model will fail 
to converge due to the inclusion of separate random effects 
for provider and family as well as an unstructured covariate 
matrix for repeated assessments in the same patient. In the 
event the full model fails to converge, we will repeat analyses 
after dropping the provider random effect. If this also fails to 
provide convergence, the unstructured covariance model for 
serial correlation will be simplified.
Similar mixed effects analyses will be used for numeric 
secondary and exploratory outcome variables, including the 
perinatal grief (secondary outcome) and most of the explor-
atory outcomes. For binary outcomes, including the decision 
quality secondary outcome, we will apply generalised esti-
mating equations (GEE) for log- binomial regression (if 
convergence is achieved) or modified Poisson regression37 
(if not) to compare the proportions of participants with the 
outcome between the intervention groups. The postdecision 
comparison will be the main comparison for evaluating the 
effects of the interventions on secondary and exploratory 
outcomes hypothesised to respond quickly to the decision 
aid (eg, parent–provider communication, self- efficacy) while 
the 3- month comparison will represent the main treatment 
contrast for outcomes hypothesised to respond over a longer 
time (eg, grief, decision regret).
Non-randomised comparisons of decision aid only versus control 
group
The primary outcome, distress, will be compared between 
the groups receiving the decision aid and the control 
group using an extension of the linear mixed effects model 
described above. The model will again include fixed effects 
for provider and random effects for family and an unstruc-
tured covariance matrix to account serial correlation, but will 
be expanded to include all three treatment groups and will 
include not only the baseline distress measure but also timing 
of diagnosis, race, and literacy level as covariates to reduce 
bias in these non- randomised comparisons. The comparison 
of decision aid without values clarification method versus 
control will represent the primary treatment comparison to 
evaluate the effect of the decision aid. The comparison of 
decision aid with values clarification method versus control 
will provide a secondary assessment of the combined effect 
of decision support and values clarification method together. 
Similar extensions using linear mixed models for numeric 
outcomes and GEE for binary or categorical outcomes will 
be applied for additional non- randomised comparisons 
between the decision support and control groups.
Missing data
The proposed analyses of the primary and numeric secondary 
and exploratory outcomes apply likelihood- based inference 
and will thus remain approximately unbiased in the presence 
of missing data so long as the pattern of missingness follows a 
missing at random mechanism.38 To evaluate risk of bias from 
missing data patterns which depend on measured factors not 
included in the analytic models, participant characteristics 
will be compared between participants with complete data 
for the primary and main secondary outcomes and those 
participants with incomplete data. If substantial imbalances 
are detected, or if >10% of participants have missing data 
for a primary or secondary outcome, multiple imputation 
will be used to impute missing outcome measurements. 
The multiple imputation will be performed with a Markov 
Chain Monte Carlo algorithm using an imputation model 
incorporating each analysis variable as well as auxiliary vari-
ables that are related to the probability of missingness.39 
Rubin’s formulae will be used to account for the uncertainty 
introduced by the missing data. When data are missing for 
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procedures rather than deleting participants listwise from 
the analysis.38
ETHICS AND DISSEMINATION
This study was approved by the Institutional Review Board 
(IRB), and continues to be reapproved yearly according to 
the IRB’s standards. Important modifications made to the 
data collection routine section of the IRB application will be 
reported in the findings if those changes are found to have 
impacted the data.
Consent to participate in the study is obtained from 
participants when they fill out the baseline survey. As this 
is a low- risk study, no signature is required. All survey data 
will be deidentified before sharing the results, posing no 
risk to participant confidentiality. Access to the data may 
be granted to outside parties on a case- by- case basis by the 
discretion of the PI. Study modifications and results will 
also be reported on  ClinicalTrials. gov. In addition, find-
ings will be disseminated through presentations at scien-
tific meetings and publications in peer- reviewed journals.
DISCUSSION
Parents of a fetus or neonate diagnosed with a life- 
threatening congenital heart defect are confronted with a 
significant and challenging decision between termination 
(when diagnosed prenatally), palliative care or surgery.5–8 
This preference- sensitive decision should be supported 
through SDM whereby the family and providers can mutu-
ally engage in treatment decision making which is driven 
by what matters most to families and understanding of 
the diagnosis and treatment options.20 21 Decision aids 
are one approach to facilitate SDM.40 This study aims to 
evaluate the effect of a novel, family- centred decision aid 
on parent mental and physical health, decision making 
and clinical encounter outcomes. Few studies have exam-
ined how effective values clarification methods, which 
the IPDAS standards collaborative added as criteria for 
decision aids, are when combined with a decision aid 
in clinical contexts.26 Therefore, this study also aims to 
contribute to the literature by examining the effect of 
the decision aid with and without a values clarification 
method.
There are some potential study limitations to note that 
are common when studying paediatric conditions. There 
may be issues with meeting sample size requirements 
for sufficient statistical power. This issue could arise due 
to the rarity of severe CHD diagnoses and the potential 
for high attrition as parents are under high emotional 
burdens and distress surrounding the diagnosis, decision, 
and coping or managing the treatment they choose. Our 
study design attempts to proactively address these issues. 
For instance, we will use extensive follow- up procedures 
via telephone or in person to minimise attrition. If ques-
tionnaire burden results in higher than expected attri-
tion, we will limit questions to the primary and secondary 
outcomes.
Our study will significantly contribute to advancing 
decision support and counselling for parents making 
life- altering decisions for their fetus or neonate with a 
life- threatening heart defect. This important and innova-
tive decision aid and values clarification method will also 
build on the dearth of decision aids in paediatric, surro-
gate decision- making contexts.
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